Edition:
United States

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

9.90USD
21 Aug 2017
Change (% chg)

-- (--)
Prev Close
$9.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
285,020
52-wk High
$12.05
52-wk Low
$2.65

SGMO.OQ

Chart for SGMO.OQ

About

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company... (more)

Overall

Beta: 3.13
Market Cap(Mil.): $827.75
Shares Outstanding(Mil.): 83.61
Dividend: --
Yield (%): --

Financials

  SGMO.OQ Industry Sector
P/E (TTM): -- 78.33 32.62
EPS (TTM): -0.81 -- --
ROI: -28.31 3.21 14.94
ROE: -32.60 5.08 16.18

BRIEF-Sangamo Therapeutics reports Q2 loss per share $0.17

* Sangamo Therapeutics reports second quarter 2017 financial results

Aug 09 2017

BRIEF-Sangamo Therapeutics appoints Roger Jeffs, Joseph Zakrzewski to its board

* Sangamo Therapeutics appoints Roger Jeffs, PH.D. and Joseph S. Zakrzewski to its board of directors

Jun 29 2017

BRIEF-Sangamo Therapeutics announces closing of public offering of common stock

* Sangamo Therapeutics announces closing of public offering of common stock and exercise in full of underwriters' option to purchase additional shares of common stock Source text for Eikon: Further company coverage:

Jun 26 2017

BRIEF-Sangamo announces pricing of $72.5 mln public offering of common stock

* Sangamo therapeutics announces pricing of $72.5 million public offering of common stock

Jun 21 2017

BRIEF-Sangamo Therapeutics announces proposed public offering of common stock

* Sangamo Therapeutics announces proposed public offering of common stock Source text for Eikon: Further company coverage:

Jun 20 2017

BRIEF-Adage Capital Partners L.P. reports 5.56 pct passive stake in Sangamo Therapeutics

* Adage Capital Partners L.P. reports 5.56 percent passive stake in Sangamo Therapeutics Inc as of May 25, 2017 Source text: (http://bit.ly/2rAv5jo) Further company coverage:

Jun 02 2017

BRIEF-Sangamo Therapeutics enters into amended and restated agreement with Cowen and Company

* On May 26 co entered into amended and restated at-market offering program sales agreement with Cowen and Company

May 26 2017

BRIEF-Sangamo Therapeutics files for mixed shelf offering of up to $200 mln

* Sangamo Therapeutics Inc files for mixed shelf offering of up to $200 million - SEC filing Source text for Eikon: (http://bit.ly/2qs1aWo) Further company coverage:

May 26 2017

Pfizer strikes deal with Sangamo, broadening hemophilia pipeline

NEW YORK U.S. drugmaker Pfizer Inc said on Wednesday it reached an agreement with Sangamo Therapeutics Inc for rights to its gene therapy programs to treat the rare blood-clotting disorder hemophilia A, under which Pfizer will pay $70 million upfront.

May 10 2017

Pfizer strikes deal with Sangamo, broadening hemophilia pipeline

NEW YORK, May 10 U.S. drugmaker Pfizer Inc said on Wednesday it reached an agreement with Sangamo Therapeutics Inc for rights to its gene therapy programs to treat the rare blood-clotting disorder hemophilia A, under which Pfizer will pay $70 million upfront.

May 10 2017

Competitors

  Price Chg
Novo Nordisk A/S (NOVOb.CO) kr.290.10 +2.50
Pfizer Inc. (PFE.N) $32.76 --
Novartis AG (NOVN.S) CHF80.40 +0.45
Merck & Co., Inc. (MRK.N) $61.97 --
Roche Holding Ltd. (ROG.S) CHF243.10 +2.70
Roche Holding Ltd. (RO.S) CHF246.50 +2.30
Bayer AG (BAYGn.DE) €107.65 +1.25
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €82.10 +0.20
GlaxoSmithKline plc (GSK.L) 1,493.19 +13.69

Earnings vs. Estimates